

Hanmi

Hanmi VISION DAY

2025. 12. 4.

Hanmi

Hanmi Science

Jae-Kyo Kim

CEO of Hanmi Science

Hanmi Group Professional Executives



Jae-Kyo Kim

CEO of Hanmi Science



Jae-Hyun Park

CEO of Hanmi Pharm



Dong-Hwan Lee

CEO of JVM



2025 Hanmi VISION DAY



Hanmi

Beyond the Past,

**“Once Again with
Creation and Innovation”**

Hanmi Group 2030 Growth Drivers

OBESITY



GLP-1, UCN2 and Beyond :
Establishing Market Leadership
in the Full Obesity Lifecycle

ANTI-AGING



Anti-aging :
Proactive Research &
Product/Service Development

DIGITAL HEALTHCARE



AI-Driven
Innovative Drug Development
& Digital Healthcare

ROBOTICS



Pharmacy and Hospital
Automation,
Surgical Robots



2025 Hanmi VISION DAY

Exploring Future Business and Maximizing Strategic Growth Opportunities

NEXT Hanmi

Corporate
Strategy Team

Business
Strategy Team

Enhancing Open Innovation and
Global Partnership Strategies
Innovation Division

**"Formulating and Executing
Mid- to Long-Term Management
and Business Strategies"**

**"Expanding External Connections,
Collaboration, and Partnerships"**

Strategic Planning Division

Driving Future Growth and
Supporting Commercialization

IP Team

L&D
Strategy
Team

C&D
Strategy
Team



Hanmi

2025 Hanmi VISION DAY

Mid- to Long-Term Growth Strategies and Objectives

~2025

Driving Fundamental Growth

~2030

Dual Momentum Strategy

Fundamental Growth

- ✓ R&D and New Products
- ✓ Key Product M/S Growth
- ✓ Enhancing Group Synergies
- ✓ Enhancing Operational Efficiency (Smart Factory, etc.)

Innovative Growth

- ✓ Open Innovation
- ✓ Tech Incubating
- ✓ Expanding Portfolio and Value Chain
- ✓ Expanding Global Footprint

2030 Sales Target
KRW 5 Trillion

Innovative Growth

KRW 2 Trillion

KRW 3 Trillion

Fundamental Growth



2025 Hanmi VISION DAY

Hanmi

Hanmi Science

Strategy / Healthcare

Seong-Hoon Kim

Head of Strategic Planning Division (Acting Head of Healthcare Division), Hanmi Science

Driving Innovative Growth


Linked to Fundamental Growth



Restructuring and Expanding Pharmaceutical and Non-Pharmaceutical(Medtech, Healthcare) Business

Group Portfolio Strategy : Rebalancing & Reinforcement

Building a Balanced Business Structure → Timely Response to Opportunities and Risks, Maximizing Corporate Value




2025 Hanmi VISION DAY

Dual Momentum Strategy : Pharmaceuticals

Driving First-in-Class and Best-in-Class Drug Development

Fundamental Growth via In-House Pharma + Innovative Growth via Holding Company



2025 Hanmi VISION DAY

Dual Momentum Strategy : Medtech & Healthcare Business

Driving Expansion of Business Areas and Value Chain

Affiliate-driven growth and new field exploration + Holding company-led investment and M&A strategy

JVM

- Vertical Expansion into Global Distribution Networks and Components
- Exploring Automation Solutions, Robotics, and S/W Beyond Dispensing Systems

Medical Devices

- Expanding from Surgical Therapeutics to Devices & Equipment
- Medtech Collaboration and Strategic Partnerships
- Global Distribution for Export Growth



Online Pharm

- Hospital-Pharmacy Linked Business Expansion (Kiosk, KEIDAS, etc.)
- Innovating Pharmacy-Friendly Services

Consumer

- Building Product Competitiveness Through R&D Internalization
- Developing Future Growth Areas (Senior, Kids)
- Strategic Investments in Cosmetics, Health Supplements, Raw Materials, Components, and Equipment



2025 Hanmi VISION DAY

Full-Scale Global Expansion: Building Key Regional Hubs



2025 Hanmi VISION DAY


Hanmi Group

Healthcare Business Growth

B2C Brand Development and Medical Device Expansion

for Market Leadership

2030 Target Revenue



Key Growth Indicators

CAGR

33%



Innovative Growth

KRW

260 billion



- Building Beauty Care Brands and Entering the Care Food Market
- Expanding into Medical Device Segment (e.g., Surgical Robots)



2025 Hanmi VISION DAY

B2C Brand Development and Medical Device Expansion

Fundamental Growth
KRW 240 Billion

Innovative Growth
KRW 260 Billion

Soy Milk / Beverages



Soy Milk : Expanding Functional Product Lines
Functional Ingredient-Infused Beverages

Golden Kids



Expanding Product Lineup for Golden Kids
Height Growth and Child Nutrition Supplements

Medical Devices



Sustaining Growth in Surgical Therapeutics
(Adhesion Barrier, Hemostatics, Wound Dressings)
Expanding Sourcing of Medical Materials
and Entering Device/Equipment Markets



2025 Hanmi VISION DAY

Expanding Consumer Health and Medical Device Business Areas

Fundamental Growth
KRW 240 Billion

Innovative Growth
KRW 260 Billion

Consumer Healthcare

Beauty Care Brand Development

'Advanced Derma Science, Expansion into Devices and Inner Beauty'

Care Food Market Entry


'Product Development (Including FSMP*) and B2C/B2B Channel Expansion'

*Food for Special Medical Purposes

Innovating Health Functional Foods

'Core Brand Development and Chronic Disease Supplements'

Medtech/Healthcare Expansion



2025 Hanmi VISION DAY



Hanmi

Hanmi Pharmaceutical

Jae-Hyun Park

CEO of Hanmi Pharm

Advancing to Global Top Tier Beyond Korea Through Creation and Innovation



2025 Hanmi VISION DAY

Fundamental Growth

- ✓ Evidence-Based Differentiated Marketing for Chronic Disease Products
- ✓ Annual Launch of One or More Blockbuster Products
- ✓ Global Target: Enhanced R&D and Customized Product Development
- ✓ Smart Innovation-Driven Global Manufacturing Hub



Innovative Growth

- ✓ Driving New Growth Through Open Innovation
- ✓ Leading the Next-Generation Treatment Paradigm (Obesity, Anti-aging, Oncology)
- ✓ Research Across Diverse Modalities
- ✓ R&D Innovation Based on AI-Bioinformatics

Innovative Pipelines

20+

Blockbuster Products

5+

Domestic / Overseas Sales

KRW 1.9T/1T+

Unit : Trillion KRW

5-Year Total L/O

KRW 1T+

* Upfront + Milestones Only


Synthetic and Bio Manufacturing

Global Hub



2025 Hanmi VISION DAY

2030 Target Revenue



Key Growth Indicators

Average Annual Sales Growth

20%



Innovative Growth

KRW 1.3 Trillion



2025 Hanmi VISION DAY

"First Mover & Top Tier, Expansion"

Fundamental Growth

Annual Launch of
One or More Blockbuster
Flagship Product*

Pioneering New Trend,
Setting Key Milestones

*Beyond Blockbuster,
Iconic and High-End

Drug Repositioning
& Value-up

Efpeglenatide
Additional Clinical Trials for
Diabetes and DTx

Rolontis
A.I Formulation Launch

Belvarafenib
Domestic Phase 2
Development First

Amoprel
World's First Low-Dose
Triple Combination
for Initial Hypertension

Innovative Growth

Global Target,
Customized Product
Development

New Product Development
for Upcoming Global Patent
Expirations

Global Flagship Product
Launch Strategy

Building Global Portfolio
Through Development
Planning & Clinical Expertise

Global Pharma
Co-Promotion
(Partnerships and New Drug L/I)

Jul 2025, Co-Promotion of
'Obodense' with
Samsung Bioepis

Oct 2025, Co-Promotion of
COPD Treatment with
Boehringer Ingelheim

Future Collaborations
in Progress



"First Mover & Top Tier, Expansion"


Annual Launch of One or More Blockbuster Flagship Product

Drug Repositioning Value-up

Global Target Customized Product Development

Global Pharma Co-Promotion (Partnerships and New Drug L/I)

New Product Launch



Marketing Strategy

Clinical Data-Driven Credibility | Early & Combo Therapy Market Leadership | Securing Growth Drivers Through New Drug and Package Strategies

Flagship Blockbuster



2025 Hanmi VISION DAY

"First Mover & Top Tier, Expansion"

Annual Launch of One or More Blockbuster Flagship Product

Drug Repositioning Value-up

Global Target Customized Product Development

Global Pharma Co-Promotion (Partnerships and New Drug L/I)

19 Key New Drugs and Products Under Clinical Trials and Bioequivalence Studies

Stage	Drug Approval / Release	Formulation Development/Preclinical	Phase 1, 2	Phase 3
Cardiovascular/ Metabolism/ Cancer/ Respiratory	1st Combi Amoprel Hypertension 2025	1st Formulation Rolontis A.I Neutropenia 2026	1st Formulation HIP2503 2027	New Drug Efpeglenatide Obesity 2026
	1st Dosage Low Dose AmosartanXQ Hypertension/Dyslipidemia 2025	1st Dosage AmoprelPro 2028	New Drug Belvarafenib 2029	1st Indication HGP2304 2027
	1st Combi Empalon Duo Diabetes 2025	1st Indication HIP2303 2029	1st Combi HCP2203 2030	1st Indication Efpeglenatide Diabetes 2029
Musculoskeletal		1st Formulation HIP2404 2027		1st Indication HCP1004 2026
Gastroenterology		1st Formulation HGP2401 2028		
Urology/ Dermatology		HCP2402 2028	HGP2407 2026	
		HIP2502 2032	1st Dosage HGP2501 2027	



"First Mover & Top Tier, Expansion"

Annual Launch of
One or More Blockbuster
Flagship Product

**Drug Repositioning
Value-up**

Global Target
Customized Product
Development

Global Pharma
Co-Promotion
(Partnerships and New Drug L/I)

Efpeglenatide	Expanding Indications for Diabetes and Developing Korea's First Digital Convergent Medicine
Rolontis	Developing Auto-Injector Formulation and Same-Day Dosing Regimen
Belvarafenib	"First" Domestic Development and Commercialization of Targeted Melanoma Therapy
Amoprel	"World's First" Low-Dose Triple Combination Therapy for Initial Hypertension Treatment

New Drug

New Product



"First Mover & Top Tier, Expansion"

Annual Launch of
One or More Blockbuster
Flagship Product

Drug Repositioning
Value-up

**Global Target,
Customized Product
Development**

Global Pharma
Co-Promotion
(Partnerships and New Drug L/I)



**New Product Development
Aligned with Global Patent Expiry**
Conventional Overseas Expansion of existing
Domestic Product leads to delayed entry
**Target Product and Market Selection
Based on Patent Expiry and Global Analysis**

Global Blockbuster Strategy
Using Market Insights and Planning Expertise
**to Assess Regional Characteristics and
Analyze Market & Product Trends Globally**
Clinical Strategies for Global Expansion and
Multinational Trials with Target Country Patients



Securing Commercialization Potential and Market Competitiveness



"First Mover & Top Tier, Expansion"

Annual Launch of
One or More Blockbuster
Flagship Product

Drug Repositioning
Value-up

Global Target
Customized Product
Development

Global Pharma
Co-Promotion
(Partnerships and New Drug L/I)

SAMSUNG Obodense (Prolia BS)
BIOEPIS Co-Promotion

 **Boehringer
Ingelheim** Three COPD
Treatments
Co-Promotion

 **FRESENIUS
KABI** Low Osmo Peri Inj.
Co-Promotion

teva Ajovy Auto Injector
Co-Promotion



Future Collaborations In Progress



2025 Hanmi VISION DAY

Beijing Hanmi Pharmaceutical

: Hanmi Group's Strategic Foothold for Entry into China

30th Anniversary of Beijing Hanmi in 2026: A New Phase of Growth

01 Construction of the Beijing Integrated Complex


02 Expansion of New Drug and New Product Pipelines

03 Expansion into Food and Health Functional Food Businesses

04 Strengthening Focused Execution in the ETC (Ethical Drug) Market



■ New Businesses (Food, Health Functional Foods)
 ■ New Products (Pharmaceuticals)
 ■ Existing Products




2025 Hanmi VISION DAY

Hanmi Fine Chemical : Global Standard GMP Plant

Building on a Generic API Foundation with
Added CDMO Competitiveness

Evolving into a
Global High-Tech CDMO Company



2025 Hanmi VISION DAY



Hanmi

R&D Center

In-Young Choi

PhD, Head of R&D Center

2025 Key Achievements in New Drug R&D

Accelerating Clinical Development of Innovative Drug Pipelines, Securing First-in-Class Assets, and Demonstrating R&D Capabilities through Multiple Next-Generation Oncology Programs Based on Novel Modalities

Highlighting Academic Achievements Alongside Clinical Progress in Core Obesity and Metabolic Disease Therapies

HM15421(LA-GLA)

Initiation of Phase 1/2 Clinical Trials

Phase 1/2 clinical trial successfully initiated in April 2025

Joint research collaboration with GC Biopharma

HM15275(LA-GLP/GIP/GCG)

Completion of Phase 1 and Initiation of Phase 2 Clinical Trials

Phase 2 clinical trial initiated in November 2025

Accelerated follow-on development supported by strong tolerability and safety profile

'efpeglenatide'

Phase 3 Clinical Trial, Demonstrated Favorable Efficacy and Safety

Completion of 40-week Phase 3 clinical trial in October 2025

Domestic regulatory approval in Korea expected in the second half of 2026

HM17321(LA-UCN2)

Phase 1 Clinical Trial Approval and Initiation

Phase 1 clinical trial approved and initiated in November 2025

Fastest clinical trial approval timeline to date First-in-Class asset

Research Outcomes and External Recognition

Presentation of a total of 49 research results at international scientific conferences, gaining global recognition of research capabilities

Three new programs introduced to the academic community (STING mRNA, oral GLP-1, EP300 degrader)

Pipeline Expansion through Next-Generation Modalities

Multiple First-in-Class oncology programs initiated based on next-generation modalities, including TPD, RLT, sdAb, and ADC

Continued efforts to secure future growth drivers in the oncology field




2025 Hanmi VISION DAY

Aging Is a Key Factor Increasing the Risk of Metabolic and Oncologic Diseases

- ✓ Age-related physiological decline—including cellular aging, metabolic dysfunction, and hormonal imbalance—contributes to metabolic diseases, which show the highest prevalence among age-related conditions.
- ✓ GLP-1-based therapies reduce inflammation and neuroinflammation, contributing to delayed aging and extension of healthy lifespan (Daniel J. Drucker)
- ✓ Due to factors such as genomic instability, dysregulation of the cell cycle, immune system decline, and chronic inflammation, cancer incidence increases sharply with advancing age

Shared Biological Pathways



Role of GLP-1 Therapies in Anti-Aging

Science Current Issue First release papers Archive

HOME > SCIENCE > VOL. 385, NO. 6706 > THE BENEFITS OF GLP-1 DRUGS BEYOND OBESITY

PERSPECTIVE MEDICINE


The benefits of GLP-1 drugs beyond obesity

Glucagon-like peptide-1-based medicines have weight loss-independent actions


DANIEL J. DRUCKER [Authors Info & Affiliations](#)

SCIENCE • 18 Jul 2024 • Vol 385, Issue 6706 • pp. 258-260 • DOI:10.1126/science.adn4128

Cancer Incidence Increases with Age



Persistently High Unmet Needs Driven by the Continued Increase in Cancer Incidence



2025 Hanmi VISION DAY

“Shaping the Future of Aging with R&D Leadership”





2025 Hanmi VISION DAY

Paradigm Shift, Aging & Future



Establishment of Advanced R&D Infrastructure and Global-Standard Technological Capabilities

Leading the Next-Generation Drug Discovery Paradigm through Internalization of New Technologies such as AI and BI/Omics



ADC: Antibody drug conjugate, TPD: Target protein degradation, TPM: Target protein modulator, CGT: Cell and Gene Therapy, sdAb: Single-domain antibody, RPT: Radiopharmaceutical Therapy, AI: Artificial Intelligence, BI: Bioinformatics



Paradigm Shift, Aging & Future

 **Advancement of the H.O.P Project**
Addressing the Next-Generation Obesity Treatment Market → Metabolic to Longevity 

Enhancing the Potential of Triple-Agonist Therapies as Advanced Obesity Treatments



Global Top-Tier Development of Triple-Agonist Therapies

HM15275 : Expected to Deliver Bariatric Surgery-Level Efficacy, Targeting Launch in Korea in 2030 and Globally in 2031

Improving the Quality of Weight Loss



Development of a Novel Muscle-Enhancing Therapy Compatible with Existing GLP-1 Treatments

HM17321 : A UCN2 Analog Suitable for Monotherapy, with an Additional Pipeline Designed to Improve Muscle Quality and Mass

Maximizing the Obesity Treatment Portfolio and Pivoting Toward Health Promotion



Leveraging Shared Pathophysiological Mechanisms Between Obesity and Aging to Further Elucidate Anti-Aging Effects (**efpeglenatide, HM15725**)

Delivering Solutions for Health Promotion and Better Quality of Life (**via Novel Therapeutics**)



Paradigm Shift, Aging & Future



Leadership in Anti-Aging & Rejuvenation

Pioneering the Therapeutic Market Based on Proactive Aging Research

Hanmi's Strategy for Entering the Aging & Longevity Market



Human-Omics based approach
 Biological aging clock
 Proteome-phenome ML model

HM15275 Ph2 Anti-aging Potential
 Blood proteomic analysis
 Effect on aging and frailty

Expansion of Anti-Aging Efficacy & Identification of New Aging Targets

Hanmi Longevity Pipelines

Direct Effects of Anti-Aging & Rejuvenation Therapies	Broader Societal Impact
Extension of Healthspan	Containment of Healthcare & Welfare Costs
Increased Labor Productivity	Addressing Low Birth Rates and Demographic Challenges
Creation of New Markets	Growth in Geriatric Disease and Oncology Markets




2025 Hanmi VISION DAY

Paradigm Shift, Aging & Future



Continuous creation of innovative new drug pipelines
 Accelerating discovery of First-in-Class new drugs through open innovation



"Open Innovation Status across Industry–Academia–Research"

AI-Based Compound Discovery	AIGEN Sciences Syntekabio	Investigator-Initiated Clinical Trials	Samsung Medical Center Seoul Asan Medical Center
Introduction of New Compounds	RAPT Allergro	Identification of New Indications	Seoul National University Hospital, Department of Neurology CHA Bundang Medical Center
Biomarker Discovery	MEDiCLS KAIST Bio and Brain Engineering BERTIS (Proteomics)	Mechanism-of-Action (MoA) Research	Seoul National University Hospital, Department of Neurology KAIST, Department of Biological Sciences NovoMeta Therapeutics

*FIC: First-in-Class



New Drug R&D Roadmap

	2026	2027	2028
efpeglenatide LAPS [®] Exd4 analog		NEWLY LAUNCHED Obesity, S.Korea Launch	Diabetes, Ph3 Readout Diabetes, NDA submission
efinopegdutide* LAPS [®] GLP/GCG agonist MSD	MASH, Ph2b Readout	MASH, Ph3 Start	
efocipegtrutide** LAPS [®] Triple agonist		MASH, Ph2b Readout MASH, Ph3 Start	
HM15275** LA-GLP/GIP/GCG	Diabetes, Ph2 Start	Ph2 Readout	Obesity, Ph3 Start Diabetes, Ph3 Start
HM17321** LA-UCN2	Ph1 SAD Readout	Obesity, Ph1 Readout	Obesity, Ph2 Start
ROLVEDON®* Assertio	AI Formulation Launch		Ph2 Readout NDA submission
belvarafenib* RAF Roche		NEWLY LAUNCHED S.Korea Launch	Ph2 Readout NDA submission IIT, Ph2 Readout
poseitinib* multi-TEC NOBO Medicine	PCNSL/DLBCL(Triple Therapy) Ph2 Readout S.Korea NDA		
tuspetinib* MKI Aptose	AML 1L(Triple Therapy) Ph1/2 Readout	AML 1L(Triple Therapy) Ph2/3 Start	
HM16390 LAPS [®] L-2 analog		Ph1 SAD Readout	
HM97662 EZH1/2		Ph1 Readout	Ph1/2 Start
HM100714 sHER2	Ph1 Start		
HM101207 SOS1		Ph1 Start	
efpegerglucagon** LAPS [®] Glucagon analog	Ph2 Readout	Ph3 Start	
sonepeglutide** LAPS [®] GLP-2 analog			SBS, Ph2 Readout SBS, Ph3 Start
HM15421** LA-GLA GC		Ph1/2 Interim Data	



2029-2030

- Filing for Approval**
 - 5 Product Launches
- Late-Stage Entry**
 - 3 Phase 2 Entries
 - 2 Phase 3 Entries
- Entered Clinical Trials**
 - 4 Phase 1 Initiations

*Existing Partnerships, **Potential Partnerships



2025 Hanmi VISION DAY



JVM


Dong-Hwan Lee

CEO of JVM



**Hospital & Pharmacy
Automation Total Solution
"Top Tier Provider"**

2030 Target Revenue



Key Growth Indicators

Average Annual Sales Growth

24%



Innovative Growth

KRW 135 billion



2025 Hanmi VISION DAY

Fundamental Growth

Core Business Expansion (Pouch)

- ✓ Strengthening product competitiveness
- ✓ New product development & Profitability enhancement



Innovative Growth

New Business Expansion (Vial, Blister)

- ✓ Development of new products/functions
- ✓ Establishment of overseas manufacturing hubs

Entry into Adjacent Businesses

- ✓ Robotics & Healthcare solutions
- ✓ Strategic partnerships and M&A

Global Partnership Reinforcement by Region

New Pouch models developed

10

Development of New Models in Addition to Vial and Blister

9

Domestic/Overseas Revenue

KRW 0.16T /0.34T

Unit : Trillion KRW

Global manufacturing operations

Expansion into adjacent industries
Strategic partnerships · M&A



2025 Hanmi VISION DAY

Strengthening Product Competitiveness Domestically and Globally - Fundamental Growth

Enhancing product competitiveness from domestic to overseas markets (10 new models to be developed by 2028)

Overseas: Development of market-tailored features and equipment

Domestic: Portfolio expansion through the launch of new equipment

Packaging: First in the industry to manufacture ISO15378-certified pouches

*Pharmaceutical Packaging Quality Certification



MENITH



NSP



DOC





JVM

2025 Hanmi VISION DAY

Expansion of CAPA and Smart Factory - Fundamental Growth

Manufacturing strategy for profitability enhancement
Quantitative growth through Capacity expansion
+ Qualitative competitiveness through Smart Factory implementation



2025 Hanmi VISION DAY

Development of Innovative Products Targeting Global Markets - Innovative Growth

Expansion of Vial and Blister products and Development of Biodegradable Packaging (9 New models by 2028)

Vial : Development of automated and feature-enhanced products



COUNTMATE



Blister : Development of large-scale and feature-enhanced products



DOB



Packaging : Development of EN and ASTM-certified biodegradable pouch packaging



2025 Hanmi VISION DAY

Establishing a Foothold for Global Market Entry - Innovative Growth

Operating a Global Manufacturing Network through Expanded Production Bases

[CHINA] Establishment of a Manufacturing Subsidiary
: Responding to China's localization policies and enhancing price competitiveness

Accelerating local production and sales expansion of equipment for the Chinese market


Reducing Costs through Optimized Component Sourcing

Meeting Rising Global Demand through Expanded Production CAPA



2025 Hanmi VISION DAY


Expansion of Robotics business, Including healthcare, S/W solutions, and AI·DX capabilities Innovative Growth



JVM

2025 Hanmi VISION DAY

Expanding Overseas Partnerships Across North America, Europe, and New Regions



2025 Hanmi VISION DAY



**Beyond Korea's No.1 ATDPS Provider,
Towards a Global Automation Solutions Leader!**





Hanmi

Financial Strategy

Byung-Hwa Shim

CFO of Hanmi Science

2030 Target Revenue

*Sum of standalone revenue
JVM consolidated revenue (Domestic + European subsidiaries)

Unit : Trillion KRW

KRW

5 Trillion*

Hanmi Science 0.8

JVM 0.5

Fine Chemical 0.2

Beijing Hanmi 0.6

Hanmi Pharm

2.9

2030 consolidated basis
Hanmi Science : 3.6
Hanmi Pharm : 3.5

+ KRW
3 Trillion

Approximately
KRW 2 Trillion

Hanmi Science 0.23

JVM 0.17

Fine Chemical 0.1

2025 consolidated basis
Hanmi Science : 1.3
Hanmi Pharm : 1.5

Beijing Hanmi 0.4

Hanmi Pharm 1.1

2025

2030



2025 Hanmi VISION DAY

2030 Target Operating Profit Margin

Hanmi Science

Strengthening Healthcare
Growth Drivers
Supporting Group Growth
Initiatives and Business
Development

*Standalone Basis

Hanmi Pharm

Enhancing Flagship Product
Competitiveness
Advancing New Growth
Engines and Innovation

*Standalone Basis

JVM

High-Value Business
Expansion
Increasing Overseas Sales
Contribution and Expanding
New S/W Business Areas

*Consolidated Basis

OPM

25% ↑

20% ↑

20% ↑

Hanmi

2025 Hanmi VISION DAY

2030 Target Investment

Investments for Future Growth and Corporate Value Enhancement to Elevate Shareholder Value

Fundamental



"KRW 500 billion"

CAPEX
Investment

Innovative



"KRW 1.5 trillion"

R&D
Investment

License
in

Strategic
Investment

Integrated Innovative Growth through R&D, strategic investment, and technology adoption.



2025 Hanmi VISION DAY

2030 Target Shareholder Value



- Minimum Dividend Policy
- Share Buyback
- Introduction of Employee RSU Program





Hanmi

A Leading Force in the History of Korea's Pharmaceutical and Biotechnology Industry.

Hanmi Group is a **Pioneer**

The background is a deep blue gradient. In the upper right, there is a faint, glowing globe with a trail of particles or a data stream extending from it. The overall aesthetic is clean and modern, with a focus on light and motion.

THANK YOU